Metastatic Prostate Cancer-A Review of Current Treatment Options and Promising New Approaches.
ADT
PSMA Bite
PSMA radioligand therapy
bispecific T-cell engager
immunotherapy
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Jan 2023
11 Jan 2023
Historique:
received:
23
11
2022
revised:
08
01
2023
accepted:
09
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Androgen deprivation therapy (ADT) alone has been the standard of care for many years in men with metastatic prostate cancer. Due to the limited survival under this monotherapy, many new treatment options have been developed in the last few years. Regarding hormone-sensitive prostate cancer, combination therapies of two or three agents of ADT, androgen receptor signaling inhibitors (ARSI) and chemotherapy have been established and led to a significant benefit in overall survival. Additionally, in patients with metastatic castration-resistant prostate cancer, there are many new therapeutic approaches. Chemotherapy alone has been the standard of care in this situation. In the last years, some new therapeutic options have been developed, which led to an improved survival after progression under chemotherapy. These therapies include ARSI, PARP inhibitors and Lu-PSMA radioligand therapy. The use of a bispecific T-cell engager (BiTE) in this setting is a new promising therapeutic approach, which has not been established as standard of care yet. The role of immunotherapy in prostate cancer is still under investigation. Overall, many new treatment options make prostate cancer therapy a challenging and promising field.
Identifiants
pubmed: 36672410
pii: cancers15020461
doi: 10.3390/cancers15020461
pmc: PMC9856730
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Future Oncol. 2021 Sep;17(25):3291-3299
pubmed: 34098744
Eur Urol. 2015 Jun;67(6):1028-1038
pubmed: 25301760
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Biochem J. 2012 Jul 1;445(1):135-44
pubmed: 22509934
Eur Urol. 2018 Jun;73(6):847-855
pubmed: 29475737
J Clin Oncol. 2019 May 1;37(13):1051-1061
pubmed: 30817251
Ann Oncol. 2019 Dec 1;30(12):1992-2003
pubmed: 31560068
N Engl J Med. 2022 Mar 24;386(12):1132-1142
pubmed: 35179323
Lancet Oncol. 2012 Oct;13(10):983-92
pubmed: 22995653
Lancet. 2021 Jul 10;398(10295):131-142
pubmed: 34246347
Antibodies (Basel). 2019 Jul 03;8(3):
pubmed: 31544847
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Prostate. 2018 Sep;78(12):889-895
pubmed: 29707790
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Ann Oncol. 2013 Jul;24(7):1813-1821
pubmed: 23535954
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
J Clin Oncol. 2021 Jul 10;39(20):2294-2303
pubmed: 33914595
Future Oncol. 2021 Aug;17(23):3017-3026
pubmed: 34044584
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
N Engl J Med. 2019 Dec 26;381(26):2506-2518
pubmed: 31566937
BMC Cancer. 2020 Dec 10;20(1):1214
pubmed: 33302918
J Clin Oncol. 2010 Mar 1;28(7):1099-105
pubmed: 20100959
J Immunother Cancer. 2021 Sep;9(9):
pubmed: 34497115
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
N Engl J Med. 2004 Oct 7;351(15):1513-20
pubmed: 15470214
Cancer Med. 2019 Aug;8(10):4644-4655
pubmed: 31270961
Ann Oncol. 2013 Sep;24(9):2402-8
pubmed: 23723295
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
Immunotherapy. 2021 Feb;13(2):125-141
pubmed: 33172323
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553